Capsule-Filtration-Enabled LNPs Target Pancreas for Precision mRNA Therapies
A Nature study introduces AH-LNP, a pancreatic-targeted lipid nanoparticle whose protein adsorption enlarges it to enable capsule-filtration–driven pancreas accumulation and receptor-mediated uptake, allowing efficient delivery of Cas9 mRNA and sgRNA for genome editing as well as mRNA encoding therapeutic cytokines. The approach yields precise pancreatic gene editing, enhances antitumor responses when combined with vaccines or CAR-T therapy across multiple pancreatic cancer models, and shows safety in several animal models including non-human primates, highlighting a promising platform for precision treatments of pancreatic diseases.